Anja Frei1, Lara Siebeling2, Callista Wolters3, Leonhard Held3, Patrick Muggensturm4, Alexandra Strassmann3, Marco Zoller5, Gerben Ter Riet2, Milo A Puhan3. 1. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland. Electronic address: anja.frei@uzh.ch. 2. Department of General Practice, Academic Medical Center, University of Amsterdam, the Netherlands. 3. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland. 4. Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland; Department of Internal Medicine, Zollikerberg Hospital, Zollikon, Switzerland. 5. Institute of General Practice and Health Services Research, University of Zurich, Switzerland.
Abstract
BACKGROUND: COPD exacerbation incidence rates are often ascertained retrospectively through patient recall and self-reports. We compared exacerbation ascertainment through patient self-reports and single-physician chart review to central adjudication by a committee and explored determinants and consequences of misclassification. METHODS: Self-reported exacerbations (event-based definition) in 409 primary care patients with COPD participating in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts (ICE COLD ERIC) cohort were ascertained every 6 months over 3 years. Exacerbations were adjudicated by single experienced physicians and an adjudication committee who had information from patient charts. We assessed the accuracy (sensitivities and specificities) of self-reports and single-physician chart review against a central adjudication committee (AC) (reference standard). We used multinomial logistic regression and bootstrap stability analyses to explore determinants of misclassifications. RESULTS: The AC identified 648 exacerbations, corresponding to an incidence rate of 0.60 ± 0.83 exacerbations/patient-year and a cumulative incidence proportion of 58.9%. Patients self-reported 841 exacerbations (incidence rate, 0.75 ± 1.01; incidence proportion, 59.7%). The sensitivity and specificity of self-reports were 84% and 76%, respectively, those of single-physician chart review were between 89% and 96% and 87% and 99%, respectively. The multinomial regression model and bootstrap selection showed that having experienced more exacerbations was the only factor consistently associated with underreporting and overreporting of exacerbations (underreporters: relative risk ratio [RRR], 2.16; 95% CI, 1.76-2.65 and overreporters: RRR, 1.67; 95% CI, 1.39-2.00). CONCLUSIONS: Patient 6-month recall of exacerbation events are inaccurate. This may lead to inaccurate estimates of incidence measures and underestimation of treatment effects. The use of multiple data sources combined with event adjudication could substantially reduce sample size requirements and possibly cost of studies. CLINICAL TRIAL REGISTRATION: www.ClinicalTrials.gov, NCT00706602.
BACKGROUND:COPD exacerbation incidence rates are often ascertained retrospectively through patient recall and self-reports. We compared exacerbation ascertainment through patient self-reports and single-physician chart review to central adjudication by a committee and explored determinants and consequences of misclassification. METHODS: Self-reported exacerbations (event-based definition) in 409 primary care patients with COPD participating in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts (ICE COLD ERIC) cohort were ascertained every 6 months over 3 years. Exacerbations were adjudicated by single experienced physicians and an adjudication committee who had information from patient charts. We assessed the accuracy (sensitivities and specificities) of self-reports and single-physician chart review against a central adjudication committee (AC) (reference standard). We used multinomial logistic regression and bootstrap stability analyses to explore determinants of misclassifications. RESULTS: The AC identified 648 exacerbations, corresponding to an incidence rate of 0.60 ± 0.83 exacerbations/patient-year and a cumulative incidence proportion of 58.9%. Patients self-reported 841 exacerbations (incidence rate, 0.75 ± 1.01; incidence proportion, 59.7%). The sensitivity and specificity of self-reports were 84% and 76%, respectively, those of single-physician chart review were between 89% and 96% and 87% and 99%, respectively. The multinomial regression model and bootstrap selection showed that having experienced more exacerbations was the only factor consistently associated with underreporting and overreporting of exacerbations (underreporters: relative risk ratio [RRR], 2.16; 95% CI, 1.76-2.65 and overreporters: RRR, 1.67; 95% CI, 1.39-2.00). CONCLUSIONS:Patient 6-month recall of exacerbation events are inaccurate. This may lead to inaccurate estimates of incidence measures and underestimation of treatment effects. The use of multiple data sources combined with event adjudication could substantially reduce sample size requirements and possibly cost of studies. CLINICAL TRIAL REGISTRATION: www.ClinicalTrials.gov, NCT00706602.
Authors: Jason D Keene; Sean Jacobson; Katerina Kechris; Gregory L Kinney; Marilyn G Foreman; Claire M Doerschuk; Barry J Make; Jeffrey L Curtis; Stephen I Rennard; R Graham Barr; Eugene R Bleecker; Richard E Kanner; Eric C Kleerup; Nadia N Hansel; Prescott G Woodruff; MeiLan K Han; Robert Paine; Fernando J Martinez; Russell P Bowler; Wanda K O'Neal Journal: Am J Respir Crit Care Med Date: 2017-02-15 Impact factor: 21.405
Authors: Ivan Kopitovic; Aleksandar Bokan; Ilija Andrijevic; Miroslav Ilic; Sanja Marinkovic; Dragana Milicic; Marija Vukoja Journal: J Bras Pneumol Date: 2017 Sep-Oct Impact factor: 2.624
Authors: Wayne H Anderson; Jae Wook Ha; David J Couper; Wanda K O'Neal; R Graham Barr; Eugene R Bleecker; Elizabeth E Carretta; Christopher B Cooper; Claire M Doerschuk; M Bradley Drummond; MeiLan K Han; Nadia N Hansel; Victor Kim; Eric C Kleerup; Fernando J Martinez; Stephen I Rennard; Donald Tashkin; Prescott G Woodruff; Robert Paine; Jeffrey L Curtis; Richard E Kanner Journal: PLoS One Date: 2017-09-21 Impact factor: 3.240
Authors: Jennifer K Quint; Elisabeth Moore; Adam Lewis; Maimoona Hashmi; Kirin Sultana; Mark Wright; Liam Smeeth; Lia Chatzidiakou; Roderic Jones; Sean Beevers; Sefki Kolozali; Frank Kelly; Benjamin Barratt Journal: NPJ Prim Care Respir Med Date: 2018-06-19 Impact factor: 2.871
Authors: Alexander C Fanaroff; Ghazala Haque; Betsy Thomas; Allegra E Stone; Lynn M Perkins; Matthew Wilson; W Schuyler Jones; Chiara Melloni; Kenneth W Mahaffey; Karen P Alexander; Renato D Lopes Journal: Trials Date: 2020-04-09 Impact factor: 2.279
Authors: Tara Lynn Barto; Diego Jose Maselli; Sarah Daignault; John Stiglich; Jared Porter; Carlye Kraemer; Gary Hansen Journal: Ther Adv Respir Dis Date: 2020 Jan-Dec Impact factor: 4.031